Table 5 Treatment rate ratios for chemotherapy alone (CT) within 6 months of diagnosis of lung, oesophageal, pancreatic and stomach cancers in 2013–2014, from a fully adjusted multivariable model with sex, age at diagnosis, deprivation, ethnicity and Charlson comorbidity index, stratified by cancer site

From: Sociodemographic variation in the use of chemotherapy and radiotherapy in patients with stage IV lung, oesophageal, stomach and pancreatic cancer: evidence from population-based data in England during 2013–2014

 

NSCLC

SCLC

Oesophagus

Stomach

Pancreas

 

%a

TRR (95% CI)

%a

TRR (95% CI)

%a

TRR (95% CI)

%a

TRR (95% CI)

%a

TRR (95% CI)

Sex

  Male

18

Ref

33

Ref

40

Ref

36

Ref

28

Ref

  Female

19

1.02 (0.97, 1.08)

33

0.98 (0.89, 1.08)

29

0.84 (0.74, 0.95)

34

0.98 (0.87, 1.11)

25

0.97 (0.88, 1.06)

  p for heterogeneityb

 

0.39

 

0.74

 

0.007

 

0.78

 

0.48

Age at cancer diagnosis

  <50

33

1.18 (1.04, 1.34)

36

0.96 (0.72, 1.26)

61

1.32 (1.08, 1.63)

61

1.17 (0.97, 1.41)

56

1.51 (1.28, 1.78)

  50–59

28

1.03 (0.95, 1.12)

30

0.79 (0.67, 0.92)

52

1.07 (0.93, 1.24)

54

1.06 (0.89, 1.26)

42

1.10 (0.97, 1.25)

  60–69

26

Ref

35

Ref

48

Ref

53

Ref

38

Ref

  70–79

19

0.78 (0.73, 0.83)

38

1.26 (1.13, 1.41)

35

0.73 (0.64, 0.82)

36

0.62 (0.54, 0.71)

25

0.68 (0.61, 0.76)

  80+

5

0.21 (0.19, 0.23)

22

0.82 (0.69, 0.98)

8

0.16 (0.12, 0.20)

10

0.16 (0.13, 0.20)

5

0.15 (0.12, 0.19)

  p for heterogeneityb

 

<0.0001

 

<0.0001

 

<0.0001

 

<0.0001

 

<0.0001

Charlson comorbidity index

  0

20

Ref

34

Ref

40

Ref

38

Ref

29

Ref

  1

14

0.84 (0.77, 0.92)

33

0.97 (0.83, 1.13)

27

0.76 (0.62, 0.93)

31

0.92 (0.76, 1.12)

23

0.85 (0.73, 0.98)

  2

12

0.72 (0.63, 0.82)

29

0.84 (0.69, 1.04)

22

0.64 (0.47, 0.86)

26

0.75 (0.57, 0.98)

18

0.76 (0.60, 0.96)

  3+

7

0.49 (0.41, 0.58)

32

1.06 (0.84, 1.33)

14

0.43 (0.28, 0.64)

15

0.53 (0.35, 0.80)

12

0.54 (0.40, 0.73)

  p for heterogeneityb

 

<0.0001

 

0.39

 

<0.0001

 

0.004

 

<0.0001

Deprivation quintile

  1: least deprived

21

Ref

32

Ref

40

Ref

38

Ref

30

Ref

  2

19

0.92 (0.84, 1.01)

33

1.05 (0.87, 1.25)

35

0.85 (0.72, 1.00)

38

1.04 (0.88, 1.24)

29

0.99 (0.87, 1.13)

  3

17

0.85 (0.77, 0.92)

32

0.97 (0.82, 1.16)

37

0.92 (0.79, 1.08)

36

0.98 (0.82, 1.18)

27

0.92 (0.80, 1.05)

  4

17

0.81 (0.75, 0.89)

34

1.10 (0.92, 1.30)

37

0.90 (0.76, 1.05)

34

0.87 (0.72, 1.03)

24

0.82 (0.71, 0.95)

  5: most deprived

17

0.77 (0.71, 0.84)

35

1.16 (0.98, 1.37)

34

0.77 (0.65, 0.91)

32

0.81 (0.68, 0.98)

24

0.78 (0.67, 0.91)

  p for heterogeneityb

 

<0.0001

 

0.13

 

0.03

 

0.02

 

0.002

Ethnicity

          

  White

18

Ref

34

Ref

37

Ref

36

Ref

27

Ref

  Non-white

25

1.10 (0.97, 1.24)

32

0.90 (0.65, 1.25)

41

1.17 (0.84, 1.63)

38

0.80 (0.65, 0.99)

31

0.96 (0.79, 1.17)

  Unknown

14

0.79 (0.67, 0.92)

25

0.83 (0.59, 1.16)

36

1.04 (0.79, 1.36)

21

0.59 (0.40, 0.87)

13

0.48 (0.35, 0.65)

  p for heterogeneityb

 

0.003

 

0.45

 

0.62

 

0.004

 

<0.0001

  1. CI confidence interval, NSCLC non-small cell lung cancer, SCLC small cell lung cancer, TRR treatment rate ratio.
  2. a Proportion of patients recorded to receive treatment in each category
  3. b Performed jointly across all categories of each variable, using a post-estimation Wald test
Back to article page